Cargando…

Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic

BACKGROUND: The quality of warfarin therapy can be determined by the time in the therapeutic range (TTR) of international normalized ratio (INR). The estimated minimum TTR needed to achieve a benefit from warfarin therapy is ≥ 60%. AIM: To determine TTR and the predictors of poor TTR among atrial fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Siew Ling, Ong, Thien Jian, Mazlan-Kepli, Wardati, Mageswaran, Annuysia, Tan, Kai Hsin, Abd-Malek, Abdul-Muizz, Cronshaw, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Retrospective Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462043/ https://www.ncbi.nlm.nih.gov/pubmed/34621493 http://dx.doi.org/10.4330/wjc.v13.i9.483

Ejemplares similares

Assessing Adherence and Persistence to Non-vitamin K Antagonist Oral Anticoagulants (NOACs) among Patients with Atrial Fibrillation in Tertiary-care Referral Centers in Malaysia
por: Kubas, Mohammed A, et al.
Publicado: (2020)

Warfarin and atrial fibrillation: from ideal to real the warfarin affaire
por: Molteni, Mauro, et al.
Publicado: (2014)

Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation
por: Marcatto, Leiliane Rodrigues, et al.
Publicado: (2016)

Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
por: Pundi, Krishna N., et al.
Publicado: (2021)

The use of warfarin in veterans with atrial fibrillation
por: Bravata, Dawn M, et al.
Publicado: (2004)

Factors influencing medication knowledge and beliefs on warfarin adherence among patients with atrial fibrillation in China
por: Zhao, Shujuan, et al.
Publicado: (2017)

Improving outpatient warfarin use for hospitalized patients with atrial fibrillation
por: Touchette, Daniel R., et al.
Publicado: (2008)

Examining warfarin underutilization rates in patients with atrial fibrillation: Detailed chart review essential to capture contraindications to warfarin therapy
por: Srivastava, Ajay, et al.
Publicado: (2008)

Atrial fibrillation bleeding risk and prediction while treated with direct oral anticoagulants in warfarin‐naïve or warfarin‐experienced patients
por: Perino, Alexander C., et al.
Publicado: (2022)

Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
por: Nelson, Winnie W., et al.
Publicado: (2014)

Time in Therapeutic Range Using a Nomogram for Dose Adjustment of Warfarin in Patients on Hemodialysis With Atrial Fibrillation
por: Defoe, Kimberly, et al.
Publicado: (2021)

The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR
por: Çelik, Ahmet, et al.
Publicado: (2016)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
por: de Padua Mansur, Antonio, et al.
Publicado: (2012)

Warfarin use in hemodialysis patients with atrial fibrillation: decisions based on uncertainty
por: Juma, Salima, et al.
Publicado: (2013)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014)

The Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial Fibrillation
por: Simon, Teresa A., et al.
Publicado: (2016)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban
por: Martins, Gabriela Lopes, et al.
Publicado: (2020)

Warfarin therapy in atrial fibrillation: assessment of patient knowledge of risks and benefits
por: Fitzgerald, P., et al.
Publicado: (2020)

Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
por: Alberts, Mark, et al.
Publicado: (2020)

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
por: Fu, Chung-Ming, et al.
Publicado: (2021)

Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation
por: Williams, Brent A., et al.
Publicado: (2017)

Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction
por: Szummer, Karolina, et al.
Publicado: (2017)

Post-polypectomy bleeding and thromboembolism risks associated with warfarin vs direct oral anticoagulants
por: Yanagisawa, Naohiro, et al.
Publicado: (2018)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis
por: Shiffman, Dov, et al.
Publicado: (2015)

Warfarin Adherence Among Patients with Atrial Fibrillation in Rural Area of Dongyang, China: A Questionnaire-Based Study
por: Chen, Huadong, et al.
Publicado: (2022)

A Quality Improvement Approach to Reduce 30-day Readmissions and Mortality in Patients with Acute Decompensated Heart Failure
por: Hoo, Yee Yin, et al.
Publicado: (2020)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

Patient adherence to warfarin therapy and its impact on anticoagulation control
por: Mayet, Ahmed Y.
Publicado: (2016)

The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden
por: Björholt, Ingela, et al.
Publicado: (2007)

International Normalized Ratio Stability in Warfarin-Experienced Patients with Nonvalvular Atrial Fibrillation
por: Nelson, Winnie W., et al.
Publicado: (2015)

Rivaroxaban equals warfarin treatment in atrial fibrillation patients at high risk of stroke
Publicado: (2010)

Uninterrupted dabigatran is safer than warfarin in patients undergoing ablation for atrial fibrillation
por: Spartalis, Michael, et al.
Publicado: (2017)

Concerns about clinical efficacy and safety of warfarin in diabetic patients with atrial fibrillation
por: Yamagishi, Sho-ichi
Publicado: (2019)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation—The EWA study
por: Jaakkola, Samuli, et al.
Publicado: (2017)

Use of simplified HAS‐BLED score in patients with atrial fibrillation receiving warfarin
por: Methavigul, Komsing, et al.
Publicado: (2019)

Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis
por: Melgaard, Line, et al.
Publicado: (2021)

Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation
por: Yoo, Seo Yeon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_stpubfbndmebe0gqgsknis24pv